Form 4: Caribou Biosciences CEO Rachel Haurwitz Reports Stock Purchase

Rachel Haurwitz, President and CEO of Caribou Biosciences, reports the purchase of 20,000 shares of common stock at an average price of $1.02 per share.

Summary

• On March 14, 2025, Rachel E. Haurwitz, the President and CEO of Caribou Biosciences, Inc., purchased 20,000 shares of the company's common stock.
• The shares were bought at a weighted average price of $1.02 per share, with individual trades ranging from $1.00 to $1.03.
• Following the transaction, Haurwitz directly owns 295,450 shares and indirectly owns 3,369,395 shares through The City Canyon Family Trust.
• This trust, dated May 31, 2021, is co-managed by Haurwitz and her spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's stock purchase is generally a good sign, but the document is simply a regulatory filing of the transaction.

Positives

• The CEO's purchase of company stock could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider transactions are closely watched by investors as they can provide insights into management's perspective on the company's valuation and future performance. This purchase by the CEO could be seen as a positive sign for Caribou Biosciences.

Stakeholder Impact

• The CEO's stock purchase may positively influence shareholder sentiment.

Key Dates